Christina Weng, MD
Qing Yu Christina Weng, MD is a physician-scientist, entrepreneur, and biotech
executive. As an attending dermatologist at the Massachusetts General Hospital and
Instructor in Dermatology at Harvard Medical School, she specializes in melanoma and
pigmentary disorders. She is the Head of Business Development & Strategy and Senior Medical Director at Kira Pharmaceuticals, a
Boston-based global biotech company developing innovative complement therapeutics.
Dr. Weng also co-founded Mymiel, a high-performance clean skincare line, where she is
the Chief Strategy Officer. She serves on the Board of Directors for the Dermatology
Innovation Forum and the Dermatology Summit.
Dr. Weng attended the California Institute of Technology, where she received her
bachelor's degrees in Biology and English with honors. She graduated Magna Cum
Laude from Harvard Medical School, where she received her medical degree and was a
medical fellow of the Howard Hughes Medical Institute. She completed dermatology
residency at the Harvard Combined Dermatology Residency Training Program with
advanced clinical training at the MGH Laser & Cosmetics Center. Her postdoctoral
research was at the Cutaneous Biology Research Center of MGH.
Dr. Weng’s bench research has focused on melanocyte biology and mechanisms
leading to pigment dysregulation, with an emphasis on clinically translatable
opportunities in pigmentary disorders and melanoma. Her work additionally explores
strategies for cutaneous drug delivery. Dr. Weng’s clinical research has led to new
guidelines recommended by the American Academy of Dermatology for drug
monitoring. She has received research grants and awards from the Howard Hughes
Medical Institute, American Skin Association, American Dermatological Association, and
National Institutes of Health. She holds one U.S. patent.
Dr. Weng is also a regularly quoted medical expert on the topics of skincare and
cosmetics, with press appearances in Tatler, Allure, The Huffington Post, and numerous
other media publications.